American Association for Cancer Research
10780432ccr140553-sup-figs1-2.pdf (197.68 kB)

Supplementary Figures 1 - 2 from Bortezomib-Induced Unfolded Protein Response Increases Oncolytic HSV-1 Replication Resulting in Synergistic Antitumor Effects

Download (197.68 kB)
journal contribution
posted on 2023-03-31, 18:07 authored by Ji Young Yoo, Brian S. Hurwitz, Chelsea Bolyard, Jun-Ge Yu, Jianying Zhang, Karuppaiyah Selvendiran, Kellie S. Rath, Shun He, Zachary Bailey, David Eaves, Timothy P. Cripe, Deborah S. Parris, Michael A. Caligiuri, Jianhua Yu, Matthew Old, Balveen Kaur

PDF file - 198KB, Supplementary Figure S1. Combinatorial treatment with bortezomib and oHSV1716 induce synergistic cell killing against S462TY malignant peripheral nerve sheath tumor (MPNST) cell. Supplementary Figure S2. Induction of ER stress and unfolded protein response (UPR) in CAL27 head and neck cancer cells treated with bortezomib.



Background: Bortezomib is an FDA-approved proteasome inhibitor, and oncolytic herpes simplex virus-1 (oHSV) is a promising therapeutic approach for cancer. We tested the impact of combining bortezomib with oHSV for antitumor efficacy.Experimental Design: The synergistic interaction between oHSV and bortezomib was calculated using Chou–Talalay analysis. Viral replication was evaluated using plaque assay and immune fluorescence. Western blot assays were used to evaluate induction of estrogen receptor (ER) stress and unfolded protein response (UPR). Inhibitors targeting Hsp90 were utilized to investigate the mechanism of cell killing. Antitumor efficacy in vivo was evaluated using subcutaneous and intracranial tumor xenografts of glioma and head and neck cancer. Survival was analyzed by Kaplan–Meier curves and two-sided log-rank test.Results: Combination treatment with bortezomib and oHSV (34.5ENVE), displayed strong synergistic interaction in ovarian cancer, head and neck cancer, glioma, and malignant peripheral nerve sheath tumor (MPNST) cells. Bortezomib treatment induced ER stress, evident by strong induction of Grp78, CHOP, PERK, and IRE1α (Western blot analysis) and the UPR (induction of hsp40, 70, and 90). Bortezomib treatment of cells at both sublethal and lethal doses increased viral replication (P < 0.001), but inhibition of Hsp90 ablated this response, reducing viral replication and synergistic cell killing. The combination of bortezomib and 34.5ENVE significantly enhanced antitumor efficacy in multiple different tumor models in vivo.Conclusions: The dramatic synergy of bortezomib and 34.5ENVE is mediated by bortezomib-induced UPR and warrants future clinical testing in patients. Clin Cancer Res; 20(14); 3787–98. ©2014 AACR.

Usage metrics

    Clinical Cancer Research



    Ref. manager